| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.517 | 0.034 | 0.517 | Antiobesity | 0.446 0.05 DBMET00905 | ||
| 0.524 | 0.043 | 0.524 | Analgesic | 0.513 0.045 DBMET00905 | ||
| 0.439 | 0.004 | 0.439 | Ca(v)3.3 blocker | 0.406 0.005 DBMET00905 | ||
| 0.345 | 0.006 | 0.345 | Nav1.3 sodium channel blocker | 0.247 0.014 DBMET00905 | ||
| 0.33 | 0.01 | 0.33 | Anesthetic local | 0.29 0.013 DBMET00905 | ||
| 0.396 | 0.093 | 0.397 | Cyclophilin D inhibitor | 0.397 0.092 DBMET00905 | DBMET00905 | |
| 0.324 | 0.039 | 0.324 | Potassium channel blocker | 0.189 0.1 DBMET00905 | ||
| 0.28 | 0.003 | 0.28 | Melanocortin 5 antagonist | 0.224 0.004 DBMET00905 | ||
| 0.317 | 0.044 | 0.317 | Potassium channel (Voltage-sensitive) blocker | 0.19 0.103 DBMET00905 | ||
| 0.312 | 0.051 | 0.312 | Cardiotonic | 0.275 0.067 DBMET00905 | ||
| 0.267 | 0.007 | 0.267 | Nav1.5 sodium channel blocker | 0.188 0.015 DBMET00905 | ||
| 0.272 | 0.014 | 0.272 | Sodium channel blocker | 0.174 0.043 DBMET00905 | ||
| 0.285 | 0.041 | 0.365 | Tyrosine 3 hydroxylase inhibitor | 0.365 0.013 DBMET00905 | DBMET00905 | |
| 0.254 | 0.014 | 0.254 | Sodium channel (voltage-gated) blocker | 0.165 0.045 DBMET00905 | ||
| 0.216 | 0.009 | 0.216 | CXC chemokine 4 receptor antagonist | 0.207 0.01 DBMET00905 | ||
| 0.204 | 0.007 | 0.204 | Nav1.8 sodium channel blocker | 0.145 0.014 DBMET00905 | ||
| 0.196 | 0.004 | 0.196 | Glycine transporter inhibitor | 0.114 0.009 DBMET00905 | ||
| 0.273 | 0.089 | 0.273 | Nootropic | 0.219 0.135 DBMET00905 | ||
| 0.313 | 0.146 | 0.404 | Calcium channel L-type activator | 0.404 0.079 DBMET00905 | DBMET00905 | |
| 0.187 | 0.035 | 0.187 | Calcium channel blocker | 0.119 0.089 DBMET00905 | ||
| 0.179 | 0.029 | 0.179 | Nav1.6 sodium channel blocker | 0.142 0.064 DBMET00905 | ||
| 0.215 | 0.066 | 0.23 | Nitric-oxide synthase stimulant | 0.23 0.049 DBMET00905 | DBMET00905 | |
| 0.175 | 0.028 | 0.175 | Sphingosine 1-phosphate receptor 5 antagonist | 0.168 0.036 DBMET00905 | ||
| 0.269 | 0.125 | 0.269 | Calcium channel activator | 0.254 0.142 DBMET00905 | ||
| 0.151 | 0.008 | 0.151 | Melanocortin antagonist | 0.107 0.011 DBMET00905 | ||
| 0.184 | 0.041 | 0.184 | Nav1.2 sodium channel blocker | 0.136 0.067 DBMET00905 | ||
| 0.183 | 0.041 | 0.198 | Hemostatic | 0.198 0.033 DBMET00905 | DBMET00905 | |
| 0.156 | 0.016 | 0.156 | ABCA1 expression enhancer | 0.148 0.018 DBMET00905 | ||
| 0.137 | 0.007 | 0.137 | Ca(v)3.1 blocker | 0.131 0.008 DBMET00905 | ||
| 0.149 | 0.02 | 0.149 | Acetylcholine nicotinic antagonist | 0.125 0.028 DBMET00905 | ||
| 0.141 | 0.013 | 0.141 | Neuronal nicotinic receptor antagonist | 0.115 0.019 DBMET00905 | ||
| 0.14 | 0.012 | 0.14 | CXC chemokine receptor antagonist | 0.135 0.013 DBMET00905 | ||
| 0.21 | 0.084 | 0.21 | HERG channel blocker | |||
| 0.156 | 0.033 | 0.156 | Sphingosine 1-phosphate receptor 2 antagonist | 0.156 0.034 DBMET00905 | ||
| 0.164 | 0.045 | 0.168 | Cholinergic antagonist | 0.168 0.043 DBMET00905 | DBMET00905 | |
| 0.198 | 0.081 | 0.204 | Psychostimulant | 0.204 0.077 DBMET00905 | DBMET00905 | |
| 0.161 | 0.044 | 0.165 | Acetylcholine antagonist | 0.165 0.043 DBMET00905 | DBMET00905 | |
| 0.146 | 0.036 | 0.146 | Calcium channel (voltage-sensitive) blocker | 0.095 0.092 DBMET00905 | ||
| 0.113 | 0.007 | 0.113 | Ca(v)3.2 blocker | 0.101 0.008 DBMET00905 | ||
| 0.098 | 0.009 | 0.098 | Sphingosine 1-phosphate receptor 3 antagonist | 0.095 0.009 DBMET00905 | ||
| 0.093 | 0.008 | 0.093 | Growth hormone secretagogue receptor agonist | 0.059 0.016 DBMET00905 | ||
| 0.094 | 0.013 | 0.094 | Potassium channel (Tandem pore domain) blocker | 0.079 0.036 DBMET00905 | ||
| 0.089 | 0.014 | 0.089 | Nicotinic receptor alpha7 subunit antagonist | 0.065 0.024 DBMET00905 | ||
| 0.094 | 0.022 | 0.094 | Secretase beta inhibitor | 0.081 0.035 DBMET00905 | ||
| 0.084 | 0.014 | 0.094 | Sphingosine kinase inhibitor | 0.094 0.009 DBMET00905 | DBMET00905 | |
| 0.086 | 0.022 | 0.086 | Orexin receptor antagonist | |||
| 0.084 | 0.021 | 0.084 | Calcium channel T-type blocker | 0.054 0.048 DBMET00905 | ||
| 0.096 | 0.034 | 0.096 | Dopamine D2 antagonist | 0.084 0.038 DBMET00905 | ||
| 0.11 | 0.05 | 0.11 | Antiadrenergic | 0.101 0.055 DBMET00905 | ||
| 0.107 | 0.047 | 0.107 | Glutamate (mGluR7) agonist | |||
| 0.097 | 0.038 | 0.097 | Histamine H2 receptor antagonist | |||
| 0.108 | 0.049 | 0.108 | Adrenaline antagonist | 0.099 0.054 DBMET00905 | ||
| 0.073 | 0.016 | 0.073 | Potassium channel (Inward rectifier) blocker | 0.052 0.032 DBMET00905 | ||
| 0.059 | 0.003 | 0.059 | 5 Hydroxytryptamine 4 agonist | 0.042 0.004 DBMET00905 | ||
| 0.127 | 0.071 | 0.127 | Antibacterial (Helicobacter pylori) | 0.126 0.073 DBMET00905 | ||
| 0.108 | 0.052 | 0.108 | Alpha adrenoreceptor antagonist | 0.084 0.068 DBMET00905 | ||
| 0.121 | 0.066 | 0.131 | Acetylcholine muscarinic antagonist | 0.131 0.058 DBMET00905 | DBMET00905 | |
| 0.06 | 0.007 | 0.06 | Glucose-6-phosphate dehydrogenase inhibitor | 0.059 0.007 DBMET00905 | ||
| 0.165 | 0.112 | 0.165 | Anticonvulsant | |||
| 0.068 | 0.017 | 0.068 | Prolyl endopeptidase inhibitor | 0.06 0.025 DBMET00905 | ||
| 0.081 | 0.033 | 0.081 | Nav1.7 sodium channel blocker | |||
| 0.106 | 0.059 | 0.106 | Nav1.1 sodium channel blocker | 0.105 0.06 DBMET00905 | ||
| 0.08 | 0.034 | 0.08 | Orexin receptor 1 antagonist | |||
| 0.056 | 0.011 | 0.058 | Sphingosine kinase 1 inhibitor | 0.058 0.01 DBMET00905 | DBMET00905 | |
| 0.104 | 0.059 | 0.104 | Chemokine receptor antagonist | 0.091 0.073 DBMET00905 | ||
| 0.088 | 0.043 | 0.088 | Dopamine antagonist | 0.079 0.048 DBMET00905 | ||
| 0.083 | 0.039 | 0.083 | Epoxide hydrolase inhibitor | |||
| 0.054 | 0.011 | 0.054 | Phenylethanolamine N methyltransferase inhibitor | 0.053 0.012 DBMET00905 | ||
| 0.134 | 0.095 | 0.134 | Anticoagulant | 0.125 0.105 DBMET00905 | ||
| 0.082 | 0.042 | 0.083 | Sphingosine 1-phosphate receptor antagonist | 0.083 0.04 DBMET00905 | DBMET00905 | |
| 0.053 | 0.014 | 0.053 | Somatostatin 4 agonist | 0.052 0.014 DBMET00905 | ||
| 0.06 | 0.022 | 0.06 | Antiviral (Hepatitis D) | 0.055 0.028 DBMET00905 | ||
| 0.071 | 0.037 | 0.087 | Beta adrenoreceptor antagonist | 0.087 0.023 DBMET00905 | DBMET00905 | |
| 0.196 | 0.163 | 0.235 | Insulysin inhibitor | 0.235 0.112 DBMET00905 | DBMET00905 | |
| 0.076 | 0.044 | 0.076 | 5 Hydroxytryptamine agonist | |||
| 0.048 | 0.016 | 0.048 | Glycine transporter 1 inhibitor | |||
| 0.06 | 0.029 | 0.06 | Epithelial sodium channel blocker | 0.053 0.042 DBMET00905 | ||
| 0.035 | 0.005 | 0.036 | Somatostatin 2 agonist | 0.036 0.005 DBMET00905 | DBMET00905 | |
| 0.041 | 0.013 | 0.041 | Tryptophan 5 hydroxylase inhibitor | 0.036 0.024 DBMET00905 | ||
| 0.042 | 0.016 | 0.043 | Somatostatin agonist | 0.043 0.015 DBMET00905 | DBMET00905 | |
| 0.168 | 0.144 | 0.168 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.065 | 0.042 | 0.065 | 5 Hydroxytryptamine 2A agonist | 0.06 0.047 DBMET00905 | ||
| 0.112 | 0.089 | 0.112 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.057 | 0.035 | 0.064 | Glucosylceramidase inhibitor | 0.064 0.027 DBMET00905 | DBMET00905 | |
| 0.126 | 0.104 | 0.139 | Thrombolytic | 0.139 0.091 DBMET00905 | DBMET00905 | |
| 0.166 | 0.149 | 0.197 | Spasmolytic | 0.197 0.122 DBMET00905 | DBMET00905 | |
| 0.156 | 0.139 | 0.21 | Antiamyloidogenic | 0.21 0.093 DBMET00905 | DBMET00905 | |
| 0.072 | 0.055 | 0.072 | Rho-associated kinase I inhibitor | |||
| 0.037 | 0.021 | 0.037 | Ceramide glucosyltransferase inhibitor | 0.037 0.022 DBMET00905 | ||
| 0.052 | 0.038 | 0.052 | Dipeptidyl peptidase inhibitor | |||
| 0.026 | 0.014 | 0.028 | Glutamate (mGluR1) agonist | 0.028 0.011 DBMET00905 | DBMET00905 | |
| 0.048 | 0.036 | 0.048 | Nicotinic receptor alpha4 subunit antagonist | |||
| 0.032 | 0.019 | 0.032 | Potassium channel subfamily K member 3 blocker | |||
| 0.102 | 0.091 | 0.102 | Calcium channel N-type blocker | |||
| 0.079 | 0.068 | 0.079 | Alpha 2 adrenoreceptor antagonist | |||
| 0.051 | 0.041 | 0.051 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.043 | 0.033 | 0.043 | Dihydroorotase inhibitor | |||
| 0.061 | 0.052 | 0.073 | Beta 3 adrenoreceptor antagonist | 0.073 0.03 DBMET00905 | DBMET00905 | |
| 0.019 | 0.011 | 0.019 | Complement factor D inhibitor | |||
| 0.152 | 0.146 | 0.152 | MAP kinase kinase 5 inhibitor | |||
| 0.027 | 0.021 | 0.027 | Motilin receptor antagonist | 0.026 0.022 DBMET00905 | ||
| 0.09 | 0.085 | 0.09 | Alpha 2b adrenoreceptor antagonist | |||
| 0.052 | 0.048 | 0.052 | Cathepsin L inhibitor | |||
| 0.055 | 0.051 | 0.055 | TRPA1 antagonist | |||
| 0.051 | 0.047 | 0.051 | Potassium channel Kv1.5 blocker | |||
| 0.196 | 0.192 | 0.196 | Calpain 2 inhibitor | |||
| 0.049 | 0.046 | 0.056 | Alpha-mannosidase inhibitor | 0.056 0.032 DBMET00905 | DBMET00905 | |
| 0.05 | 0.047 | 0.063 | Beta 1 adrenoreceptor antagonist | 0.063 0.033 DBMET00905 | DBMET00905 | |
| 0.026 | 0.023 | 0.026 | Melatonin antagonist | |||
| 0.018 | 0.016 | 0.018 | Somatostatin 3 agonist | |||
| 0.163 | 0.166 | 0.196 | Superoxide dismutase inhibitor | 0.196 0.122 DBMET00905 | DBMET00905 | |
| 0.05 | 0.054 | 0.063 | Acetylcholine M3 receptor antagonist | 0.063 0.037 DBMET00905 | DBMET00905 | |
| 0.043 | 0.047 | 0.058 | Beta 2 adrenoreceptor antagonist | 0.058 0.026 DBMET00905 | DBMET00905 | |
| 0.048 | 0.052 | 0.052 | Sphingosine kinase 2 inhibitor | 0.052 0.044 DBMET00905 | DBMET00905 | |
| 0.032 | 0.04 | 0.042 | Dopamine D5 antagonist | 0.042 0.031 DBMET00905 | DBMET00905 | |
| 0.112 | 0.121 | 0.12 | Acetylcholine M1 receptor antagonist | 0.12 0.108 DBMET00905 | DBMET00905 | |
| 0.036 | 0.048 | 0.042 | Mannosidase inhibitor | 0.042 0.036 DBMET00905 | DBMET00905 | |
| 0.236 | 0.249 | 0.252 | 5 Hydroxytryptamine release inhibitor | 0.252 0.225 DBMET00905 | DBMET00905 | |
| 0.105 | 0.133 | 0.126 | Papain-like protease (SARS coronavirus) inhibitor | 0.126 0.069 DBMET00905 | DBMET00905 | |
| 0.114 | 0.148 | 0.147 | Melanin inhibitor | 0.147 0.086 DBMET00905 | DBMET00905 | |
| 0.103 | 0.137 | 0.118 | Vanilloid 1 agonist | 0.118 0.093 DBMET00905 | DBMET00905 | |
| 0.034 | 0.078 | 0.067 | Opioid delta receptor antagonist | 0.067 0.042 DBMET00905 | DBMET00905 | |
| 0.06 | 0.107 | 0.09 | Opioid antagonist | 0.09 0.056 DBMET00905 | DBMET00905 | |
| 0.036 | 0.09 | 0.043 | Beta adrenoreceptor agonist | 0.043 0.042 DBMET00905 | DBMET00905 | |
| 0.047 | 0.107 | 0.071 | Analgesic, opioid | 0.071 0.059 DBMET00905 | DBMET00905 | |
| 0.121 | 0.187 | 0.179 | Immunostimulant | 0.179 0.134 DBMET00905 | DBMET00905 | |
| 0.054 | 0.122 | 0.077 | Opioid kappa receptor antagonist | 0.077 0.062 DBMET00905 | DBMET00905 | |
| 0.08 | 0.15 | 0.12 | Toll-Like receptor 2 antagonist | 0.12 0.077 DBMET00905 | DBMET00905 | |
| 0.049 | 0.126 | 0.077 | Adrenaline agonist | 0.077 0.062 DBMET00905 | DBMET00905 | |
| 0.031 | 0.113 | 0.058 | Opioid mu receptor antagonist | 0.058 0.056 DBMET00905 | DBMET00905 | |
| 0.039 | 0.368 | 0.105 | Estrogen antagonist | 0.105 0.087 DBMET00905 | DBMET00905 | |
| 0.028 | 0.387 | 0.091 | Estrogen receptor beta antagonist | 0.091 0.082 DBMET00905 | DBMET00905 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |